Cautious investors push Jintian Pharma IPO price to the bottom
Pricing for Jintian Pharmaceutical Group’s IPO ended up at the bottom after a crowded Hong Kong market and a terrible debut from another listing put investors on guard
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts